enGene (NASDAQ:ENGN) Stock Rating Upgraded by Piper Sandler

enGene (NASDAQ:ENGN) was upgraded by equities research analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a report released on Thursday, Marketbeat Ratings reports. The brokerage currently has a $4.00 price objective on the stock. Piper Sandler‘s price objective would indicate a potential upside of 122.22% from the stock’s current price.

Several other research firms have also weighed in on ENGN. Citigroup lowered shares of enGene from a “market perform” rating to a “hold” rating in a research note on Friday, October 16th. HC Wainwright reissued a “buy” rating on shares of enGene in a research report on Friday, October 16th. Weiss Ratings lowered enGene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 30th. Wall Street Zen raised enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Jefferies Financial Group upgraded enGene to a “strong-buy” rating in a research note on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.45.

enGene Stock Performance

ENGN stock opened at $1.80 on Thursday. enGene has a twelve month low of $1.40 and a twelve month high of $12.25. The company has a quick ratio of 10.21, a current ratio of 10.21 and a debt-to-equity ratio of 0.11. The company has a market cap of $120.64 million, a P/E ratio of -0.87 and a beta of -0.24. The business’s fifty day moving average is $1.77 and its 200-day moving average is $4.06.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). Equities research analysts forecast that enGene will post -1.82 EPS for the current year.

Institutional Trading of enGene

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENGN. Dimensional Fund Advisors LP acquired a new stake in enGene in the first quarter valued at $251,000. Sei Investments Co. acquired a new position in shares of enGene during the 1st quarter worth about $409,000. Renaissance Technologies LLC increased its stake in shares of enGene by 651.1% during the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock worth $1,063,000 after purchasing an additional 135,318 shares during the last quarter. Monashee Investment Management LLC increased its stake in shares of enGene by 8.5% during the 1st quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock worth $2,179,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Eversept Partners LP raised its holdings in shares of enGene by 12.0% in the 1st quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock valued at $3,477,000 after purchasing an additional 54,708 shares during the period. 64.16% of the stock is owned by institutional investors.

enGene Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.